This review summarizes the evolving landscape of antithrombotic therapies for PCI, highlighting the shift towards newer agents like ticagrelor, prasugrel, and bivalirudin in specific clinical scenarios.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: